12:00 AM
Dec 13, 2010
 |  BC Week In Review  |  Company News  |  Deals

Activiomics, UCB deal

Activiomics will use its Targeted In-depth Quantification of Cell Signaling (TIQUAS) mass spectrometry technology to identify signaling...

Read the full 63 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >